Immunome (NASDAQ:IMNM) Receives Overweight Rating from Stephens

Immunome (NASDAQ:IMNM)‘s stock had its “overweight” rating reissued by research analysts at Stephens in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 target price on the stock. Stephens’ price target would suggest a potential upside of 266.75% from the company’s current price.

A number of other research analysts have also issued reports on IMNM. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Monday, March 10th. Lifesci Capital assumed coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price for the company. Finally, Guggenheim reduced their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $25.50.

Immunome Stock Down 5.5 %

Shares of NASDAQ:IMNM opened at $8.18 on Thursday. Immunome has a fifty-two week low of $8.17 and a fifty-two week high of $26.70. The firm has a 50-day simple moving average of $9.76 and a 200 day simple moving average of $11.57. The company has a market cap of $652.58 million, a PE ratio of -1.01 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. As a group, research analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Immunome in the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome in the 4th quarter worth approximately $75,000. AlphaQuest LLC raised its holdings in shares of Immunome by 786,700.0% in the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock worth $91,000 after purchasing an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Immunome in the 4th quarter worth approximately $95,000. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.